Effect of Caffeine on Cold-Stimulated Activity of Brown Adipose Tissue.
Zusammenfassung der Studie
Brown adipose tissue is important for energy balance in many animals, human infants, and even many adults, as it can 'burn' energy and convert it into heat. It is referred to as 'healthy' fat tissue and has many benefits for various metabolic diseases such as diabetes mellitus, obesity, and cholesterol metabolism disorders. Since the amount and activity of brown adipose tissue decrease with age and body weight, it has mainly been studied in animals, and we know little about how energy expenditure can be activated in adults. The natural stimulus for increased energy expenditure in brown fat is cold, presumably through the activation of so-called β-adrenergic receptors. Animal studies have shown that not only β-adrenergic receptors are important for the activation of brown adipose tissue, but also a co-activation by so-called adenosine receptors (A2A receptors) is necessary. Caffeine is an antagonist of these A2A receptors and should therefore inhibit this receptor effect. In this study, we want to take a closer look at the effect of caffeine on brown adipose tissue by administering 200 mg of caffeine and a placebo (as a control) to the study participants, followed by measuring energy expenditure using calorimetry and assessing the activity of brown adipose tissue with an FDG-PET/CT. This research project is a basic scientific clinical study aimed at clarifying how energy metabolism is activated in the human body. The study will be conducted at the University Hospital Basel.
(BASEC)
Untersuchte Intervention
We compare the effect of 200 mg of caffeine and placebo on the activity of brown adipose tissue after mild cold stimulation.
(BASEC)
Untersuchte Krankheit(en)
Healthy Volunteers
(BASEC)
- healthy volunteer subjects - moderate caffeine consumption (1 to 3 cups per day) - BMI 18.5-25 kg/m2 (BASEC)
Ausschlusskriterien
- intolerance to caffeine - thyroid disease - smokers (BASEC)
Studienstandort
Basel
(BASEC)
Sponsor
Universitätsspital Basel
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Prof. Dr. Matthias Betz
0041 61 265 5078
matthias.betz@clutterusb.chUniversitätsspital Basel Klinik Endokrinologie, Diabetologie und Metabolism Petersgraben 4 4031 Basel
(BASEC)
Allgemeine Auskünfte
University Hospital, Basel, Switzerland
0041 61 556 56 540041 61 556 56 54
matthias.betz@clutterusb.chmatthias.betz@clutterusb.ch(ICTRP)
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Datum der Bewilligung durch die Ethikkommission
11.06.2025
(BASEC)
ICTRP Studien-ID
NCT06978777 (ICTRP)
Offizieller Titel (Genehmigt von der Ethikkommission)
Effect of caffeine on cold-stimulated brown adipose tissue activity (ACROBAT Trial) (BASEC)
Wissenschaftlicher Titel
Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity (ICTRP)
Öffentlicher Titel
Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity (ICTRP)
Untersuchte Krankheit(en)
Brown Adipose Tissue (BAT) PhysiologyCold Exposure (ICTRP)
Untersuchte Intervention
Drug: Caffeine (200 mg)Drug: Placebo (ICTRP)
Studientyp
Interventional (ICTRP)
Studiendesign
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Investigator, Outcomes Assessor). (ICTRP)
Ein-/Ausschlusskriterien
Inclusion Criteria: - BMI 18.5 to 25 kg/m2 - Able to give informed consent as documented by signature - Moderate caffeine consumption (1 to 3 cups of coffee per day) - Increase of EE in response to mild cold of = 5% of REEExclusion Criteria: - Known hypersensitivity or allergy to caffeine - Concomitant medication other than prescription free analgesics (paracetamol and NSAID) and oral contraceptives - Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cardiac arrhythmia, hypertension, diabetes mellitus, hyper- or hypothyroidism) - History of depressive disorder or anxiety disorder - Smoker / habitual tobacco use - Habitual excessive alcohol use - Regular consumption of caffeine containing energy drinks - Weight change of >5% within 3 months prior to inclusion - Systolic blood pressure >140 mmHg and/or diastolic blood pressure > 95 mmHg. - Resting heart rate >90 bpm - Hypersensitivity to cold (e.g. Raynaud syndrome) - Known or suspected non-compliance, drug or alcohol abuse - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. - Enrolment of the investigator, his/her family members, employees, and other dependent persons - Enrolment into another study using ionizing radiation within the previous 12 months. - Pregnancy or lactation (ICTRP)
nicht verfügbar
Primäre und sekundäre Endpunkte
BAT SUVmean (ICTRP)
BAT SUVmax;BAT Volume;Cold induced thermogenesis (CIT);Resting energy expenditure (REE);Respiratory exchange ratio (RER):;Skin temperature;Metabolom and Lipidome profile;Caffeine and its metabolites (ICTRP)
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
Matthias Betz, Prof.Matthias Betz, Prof.Matthias Betz, Prof., Matthias.Betz@usb.chmatthias.betz@usb.ch, 0041 61 556 56 540041 61 556 56 54, University Hospital, Basel, Switzerland (ICTRP)
Sekundäre IDs
ACROBAT_V1_1 (ICTRP)
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
https://clinicaltrials.gov/study/NCT06978777 (ICTRP)
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar